别名 血管内皮生长因子A、vascular endothelial growth factor、Vascular endothelial growth factor A + [5] |
简介 Participates in the induction of key genes involved in the response to hypoxia and in the induction of angiogenesis such as HIF1A (PubMed:35455969). Involved in protecting cells from hypoxia-mediated cell death (By similarity).
Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. Binds to the NRP1/neuropilin-1 receptor. Binding to NRP1 initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development (By similarity). Also binds the DEAR/FBXW7-AS1 receptor (PubMed:17446437).
Binds to the KDR receptor but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. |
作用机制 PGF抑制剂 [+1] |
原研机构- |
在研适应症- |
非在研适应症- |
最高研发阶段批准上市 |
首次获批国家/地区 日本 |
首次获批日期2024-08-29 |
作用机制 PGF抑制剂 [+1] |
在研机构 |
原研机构 |
非在研适应症- |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2024-08-23 |
作用机制 PGF抑制剂 [+1] |
在研机构 |
原研机构 |
非在研适应症- |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2024-06-28 |
开始日期2025-05-01 |
申办/合作机构 |
开始日期2025-04-01 |
申办/合作机构 辉大(上海)生物科技有限公司初创企业 |
开始日期2025-03-01 |